Finally, the in vivo efficacy of IgA immunotherapy has been established for multiple tumor models in hCD89 transgenic mice, for example by targeting EGFR in intraperitoneal and metastatic A431 (epidermoid carcinoma) tumors, GD2 in neuroblastoma mouse models and CD20 in B cell malignancies (unpublished data and [3, 4, 35, 36]). Here, CD79A is linked to squamous cell carcinoma.